Research programme: KRAS G12V targeting therapeutics - Seed therapeutics
Latest Information Update: 12 Dec 2023
At a glance
- Originator Seed Therapeutics
- Class Antineoplastics
- Mechanism of Action KRAS protein degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 27 Oct 2023 Early research in Cancer in USA (unspecified route) (Seed therapeutics pipeline, October 2023)